Sight Sciences Inc (SGHT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Sight Sciences Inc stock (SGHT) is currently trading at $3.85. Sight Sciences Inc PS ratio (Price-to-Sales) is 2.42. Analyst consensus price target for SGHT is $8.83. WallStSmart rates SGHT as Sell.
- SGHT PE ratio analysis and historical PE chart
- SGHT PS ratio (Price-to-Sales) history and trend
- SGHT intrinsic value — DCF, Graham Number, EPV models
- SGHT stock price prediction 2025 2026 2027 2028 2029 2030
- SGHT fair value vs current price
- SGHT insider transactions and insider buying
- Is SGHT undervalued or overvalued?
- Sight Sciences Inc financial analysis — revenue, earnings, cash flow
- SGHT Piotroski F-Score and Altman Z-Score
- SGHT analyst price target and Smart Rating
Sight Sciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Sight Sciences Inc (SGHT) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Sight Sciences Inc (SGHT) Key Strengths (1)
53.20% held by institutions, strong professional interest
Supporting Valuation Data
Sight Sciences Inc (SGHT) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Modest revenue growth at 6.90%
Revenue is fairly priced at 2.42x sales
Fairly priced relative to book value
Sight Sciences Inc (SGHT) Detailed Analysis Report
Overall Assessment
This company scores 27/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 8.0/10) while 7 fall into concern territory (avg 2.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (2.42), Price/Book (2.93) suggest expensive pricing. Growth concerns include Revenue Growth at 6.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -50.70%, Operating Margin at -18.00%, Profit Margin at -49.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -50.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 6.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SGHT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SGHT's Price-to-Sales ratio of 2.42x trades at a deep discount to its historical average of 9.48x (14th percentile). The current valuation is 97% below its historical high of 70.72x set in Jul 2021, and 118% above its historical low of 1.11x in Oct 2023. Over the past 12 months, the PS ratio has expanded from ~1.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Sight Sciences Inc (SGHT) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Sight Sciences Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 77M with 7% growth year-over-year. The company is currently unprofitable, posting a -49.7% profit margin.
Key Findings
The company is unprofitable with a -49.7% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.43, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Sight Sciences Inc.
Bottom Line
Sight Sciences Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Sight Sciences Inc(SGHT)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Sight Sciences Inc. (SGHT) is a pioneering medical technology company focused on transforming the management of eye diseases through innovative surgical and non-surgical solutions, particularly targeting glaucoma care. With a robust portfolio of cutting-edge products and a strong intellectual property foundation, the company is strategically positioned to capitalize on the increasing demand for minimally invasive therapies in the ophthalmology sector. As Sight Sciences expands its distribution network and continues to drive advancements in eye care, it presents a compelling investment opportunity for institutional investors looking to engage with the dynamic healthcare market.